LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of TransEnterix, Inc. (“TransEnterix” or the “Company”) (NYSE: TRXC) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
On April 20, 2016, TransEnterix disclosed that its SurgiBot System failed to meet the United States Food and Drug Administration’s standards for substantial equivalence based upon the data and information TransEnterix submitted in its 510(k) filing.
On this news, shares of TransEnterix fell over 52% to close at just $2.27 per share on April 21, 2016.
If you purchased TransEnterix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.